newsfilter
← Earnings
Earnings Releases·

Zevra Therapeutics — Third Quarter 2026 Earnings Summary

  • Q3 2026 net revenue surged 45% year-over-year to $37.8 million, driven by $34.0 million from MIPLYFFA and $3.6 million in EAP reimbursements, resulting in a net income of $19.2 million ($0.31 basic EPS) versus a $0.5 million net loss in Q3 2025.
  • The company achieved a strengthened balance sheet with $270.9 million in cash and investments and eliminated all long-term debt, dropping from $61.9 million to zero as of September 30, 2026.
  • Strategic pipeline updates include an anticipated sNDA filing for MIPLYFFA in infants under 24 months in Q1 2027, ongoing FDA discussions for celiprolol, and a pending EU re-examination for arimoclomol.
  • Commercial progress for MIPLYFFA included 13 new prescription enrollments (197 total since launch), while the Phase 3 DiSCOVER trial for celiprolol enrolled six additional patients (72 total).
Company
ZEVRA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology